Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
June 21 2022 - 8:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage
biopharmaceutical company focused on advancing therapeutics for
rare and degenerative diseases, today announced new preclinical
data demonstrating the efficacy of the company’s 3CLpro inhibitor,
COR803, for treatment of coronavirus infections, including COVID-19
disease, caused by SARS-CoV-2 infection. In ongoing preclinical
research, COR803 successfully reduced viral load of SARS-CoV-2 in
vivo after oral treatment.
COR803 is a novel small molecule 3CLpro inhibitor discovered and
developed by Cortexyme based on its expertise in cysteine protease
inhibition. 3CLpro, or Mpro, is a validated antiviral drug target
shown to be essential in viral replication of SARS-CoV-2. Key
findings from the company’s latest mouse study of COR803
included:
- A decrease of virus titer in lung tissue after four days of
treatment compared to vehicle control;
- Comparable efficacy in animals orally dosed twice daily vs
dosed once daily; and
- Decreased lung weights in COR803 treated versus vehicle-treated
animals, indicating improved pathology. Histopathological analysis
is ongoing.
The target of COR803 is highly conserved across coronavirus
strains observed to date and, therefore, has the potential to
address both current and future coronavirus infection. Cortexyme
believes COR803 has beneficial properties over other COVID-19
therapeutics and 3CLpro inhibitors in development, including:
- A chemical reaction that leads to covalent irreversible binding
of the viral 3CLpro enzyme;
- High potency: Antiviral EC90 of 12 nM in human lung cell viral
replication assays;
- Broad spectrum activity against multiple coronaviruses;
- Highly selective for 3CLpro versus other cellular proteases,
including Cathepsin L; and
- Excellent systemic exposure in preclinical models utilizing
oral, intranasal or subcutaneous administration, allowing for
clinical use in multiple settings, such as outpatient and
inpatient.
Cortexyme is currently in IND-enabling preclinical studies for
COR803 and plans to explore partnership and licensing opportunities
to support the future development of COR803.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company focused on advancing therapeutics for
rare and degenerative diseases. The company’s innovative pipeline
includes a precision bone growth molecule and drug-targeting
platform to treat rare skeletal diseases, bone cancer and injury,
in addition to small molecule therapeutics targeting the infectious
pathogen P. gingivalis’ role in degenerative disease progression,
including for indications such as periodontal disease, oral
potentially malignant disorders, and Alzheimer’s disease, among
others. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “plan,”
“potential,” “will,” “believe,” or other similar words. Examples of
forward-looking statements include, among others; the potential
therapeutic benefits, safety and efficacy of the company’s product
candidates, including COR803, and partnership and licensing
opportunities to support future development of COR803.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict and could cause actual
results to differ materially from what the company expects.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in Cortexyme’s Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on May 10, 2022, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621005445/en/
Cortexyme Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Sep 2023 to Sep 2024